Fasenra (benralizumab) is an antibody pharmaceutical. Benralizumab was first approved as Fasenra on 2017-11-14. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. It is known to target interleukin-5 receptor subunit alpha.
|Drug Class||Monoclonal antibodies: humanized, immunomodulating|